Release Mechanisms for Profen-Loaded Nanofibers: Challenges and Opportunities

Farnaz-sadat Fattahi¹*, Tahereh Zamani²

¹Department of Textile Engineering, Isfahan University of Technology, Isfahan, Iran
²The Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

Received: April 24, 2021; revised: August 26, 2021; accepted: August 31, 2021

Abstract

Nanofibrous meshes refer to the structures made of ultra-fine polymeric fibers. Because of nanometer measure size with an excessive strength/weight ratio, they are actual suitable as a nanosystem for delivering drug molecules. Drug molecules which mixed in nanofibers, can be released from the surrounding environment by means of various mechanisms in different manners (burst release, sustainable release and tunable release). Nanofibers can be used by way of release rate controlling strategies as proper delivery structures for drug molecules. The objective of this review is to highlight the capacity of nanofibers as novel releasing substances for profens (Propionic acid derivative drugs including Carprofen; Naproxen; Fenoprofen; Flurbiprofen; Ibuprofen; Ketoprofen and Tiaprofenic acid). The profens are a class of nonselective, nonsteroidal anti-inflammatory drugs (NSAIDs). These drug molecules are derivatives of 2-phenylpropanoic acid. All contain a chiral center resulting in the formation of two enantiomers (R and S) of each profen. In this review, full information will be reported about the new progresses for release behaviors of profen molecules form the novel nanofibrous delivery systems. The drug releasing kinetics of profen molecules from nanofibers will be described briefly. The authors use more than 90 articles, books and thesis published in the case of nanofibrous profens delivery and releasing systems.

Key words

Nanofibers, Release characteristic, propionic acid derivative drugs, kinetic, sustainable release

1. Introduction

The releasing of the drug molecules from nanofibers is principally via two mechanisms which are displayed in Figure 1(1,2)

Figure 1: Mechanisms of controlling the drug release from nanofibers.

Figure 2: Propionic Acid Derivative Drugs (Profens) : General structures of R- and S-profens (The chiral centers are shown*).
There are three chief styles for the releasing trends of drug molecules from nanofibers that will be displayed briefly:

I. Sustained drug release: means gradual releasing of drug molecules and active agents over a period of time, allowing for a sustained effect. Also means timed release. Slow release. Long-active, prolonged action(3).

II. Burst drug release: means sudden releasing of drug molecules permitting a rapid appearance of active molecules(4).

III. Tunable drug release: means a particular compositional or structural parameter is tuned to give a desired release profile (5).

For the delivery of antibiotic drugs, a great initial burst is reflected a benefit since it is essential for eliminating the interfering bacteria previously they implore to proliferate. (6, 7).

1.1. Drug related factors affecting drug releasing

Nanofibers can be used by way of release rate controlling strategies. Drug release from nanofibers could be because of desorption of drug from the surface layer, diffusion from pores and or matrix degradation (8, 9). Drug associated factors affecting its releasing form nanofibers are listed in next paragraphs (10).

a) Drug loading content: Generally, higher drug loading is connected with the faster release (11).

b) Molecular weight of drug: Low molecular weight drugs are recognized for their fast release rate (12).

c) Physical state of drug: The crystalline arrangement of the drug becomes deposited on nanofiber surface and offers burst release, whereas amorphous arrangement gets deposited deeper inside and get released in a sustained style (13, 14).

d) Solubility of drug in the polymer matrix: The higher the solubility of the drug molecules in polymer matrix, the slower the release (15).

e) Drug—Polymer interactions (Chemical interactions like chemically bond drug or physical interactions like physically entrapped drug and physically adsorbed drug): Almost physical interactions between the drug molecules and polymer matrix lead to a slower release. Furthermore, direct incorporation of drug molecules in nanofibers might possibly cause undesired burst releasing (16).

1.2. Nanofibers related factors affecting drug releasing

All procedures of drug release are possible to get affected by select of inactive (polymer or other material), porosity, morphology, and geometry of nanofibers (17, 18). Nanofibers related parameters affecting drug releasing form them are reported in next section (19).

A. Randomization of nanofibers alignment: Nanofiber alignment is a various factor recognized to mark drug release and generally randomized design is associated with quicker drug release owing to improved affinity of water uptake (20).

B. Thickness of nanofibers: The releasing of drug molecules are in reverse associated with the fiber diameters. Higher fiber diameter enhances the space that drug molecules placed in the central of fibers which must diffuse from side to side for reaching the edge of the fiber. This mechanism extends release times (21, 22). Usually smaller the diameter of nanofiber quicker the release rate is reflected from it based on the statement that reduced diameter fiber has advanced surface layer area and dissolution rate (23, 24).

C. Cristalinity of nanofibers: Cristalline domains of polymers are associated with slower release of drug molecules as compared to amorphous regions (25).

D. Molecular weight: The higher the molecular weight of the polymer, the slower the release of the drug molecules from the nanofibers (26).

E. Porosity ratio of nanofibers: The porosity of nanofibers appears to affect the releasing process. A greater porosity might increase the amount of fluid that absorbs to the nanofibers and therefore quicken the releasing. Nonetheless this result might have been repressed with other parameters like the amount of hydrophilicity of nanofibers. Also the size of pores and total volume of pores meaningfully influences the diffusion of the liquid which are absorbed on the nanofibers (27). Advanced conclusions recommended that drug release cannot be only run by means of diameter and simultaneously influence of porosity is to be considered. It is repeatedly revealed that thicker nanofibers with very high porosity releasing drug quicker as compared to thinner fibers with low porosity (28, 29).

F. Specific surface area of nanofibers: Upper specific surface area delivers a greater space for communication with the nearby fluid and resulting quicker releasing of drug molecules (30, 31).

G. Fabrication method of the nanofibers (like co-electro spinning, side by side electro spinning, multi-jet electro spinning, co-axial electro spinning, emulsion electro spinning and surface immobilization): Drug molecules can be encapsulated in the different layers of nanofibers in the different fabrication techniques, so this parameter plays an important character in manipulation of the location of drug molecules in the nanofibers, which can represent a promising controlled drug release system (32).

1.3. Analyzing of the drug releasing kinetics

Drug molecules mixed in nanofibers can be released from the surrounding environment by means of a blend of various mechanisms (33). Drug molecules on the nanofibre surfaces can be dissolved and spread out of the nanofibers sheath as it is entered with body fluids. Elimination of molecule drugs on fiber surface regularly matches to the burst phase of drug releasing. The amount of burst releasing might increase with the surface area on the nanofiber, so fibers with smaller fiber diameter or upper ratio of holes can have rapidier burst release (34). The drug release kinetics can be modified by means of the selecting of polymer and controlling over the nanofiber diameter, porosity, geometry, and morphology with regulating the numerous processing variables during nanofibers production. For the assessment of the drug releasing kinetics and the determining of the mechanism in nanofibers, generally some equations are used like:

I. Peppas-korsmeyer equation (35),
II. Semi empirical releasing(srikar) model (36),
III. Crank model, siepmann model (37),
IV. Higuchi equation (38),
V. Siepmann and peppas model (39),
VI. Hopfenberg model (40, 41).
2. Propionic Acid Derivative Drugs (Profens)

The profens are a group of anti-inflammatory drugs. They reduce pain, body temperature in fever, signs of inflammation, and, in mice, slow the development of cancers. The profens are derivatives of 2-phenylpropanoic acid. All contain a chiral center resulting in the formation of two enantiomers (R and S) of each profen (Figure 2). The profens are accessible regularly as their racemates, viz., equal mixtures of the R and S stereoisomers (42).

There are a large number of profens available commercially including: Carprofen; Naproxen; Fenoprofen; Flurbiprofen; Ibuprofen; Ketoprofen; Tiaprofenic acid. In this review paper only some of them are investigated which are seen in Table 1(43).

Table 1. Chemical structures and physical/chemical properties of the studied profens(43).

| Drug         | Structure | IUPAC Name                                      | Mol. Mass, g/mol | Tm, °C | pKa | logP |
|--------------|-----------|-------------------------------------------------|------------------|--------|-----|------|
| Ibuprofen    | ![Ibuprofen Structure](image) | Iso-butylphenylpropanoic acid | 206 | 78   | 4.9 | 4.0  |
| Ketoprofen   | ![Ketoprofen Structure](image) | 2-(3-benzoylphenyl)-propanoic acid | 254 | 94   | 3.9 | 3.1  |
| Flurbiprofen | ![Flurbiprofen Structure](image) | 2-(3-fluoro-4-phenylphenyl)-propanoic acid | 244 | 111  | 4.4 | 4.2  |
| Naproxen     | ![Naproxen Structure](image) | (2S)-2-[(6-methoxy-2-yl)naphthalen-2-yl]-propanoic acid | 230 | 155  | 4.2 | 3.3  |
| Chamazulene carboxylic acid (1) | A natural profen with anti-inflammatory activity and a degradation product of proazulenic sesquiterpene lactones, e.g., matricin. | | | | | |
3. Release characteristics of propionic acid derivative drugs (profens) from nanofibers

In a novel work, PLGA/ibuprofen nanofibers were electrospun into sandwich scaffolds. *Ibuprofen* molecules have a tendency for aggregating on the surface layer of nanofibers, so initial burst releasing is occurred throughout implantation. But the sandwiched scaffolds were expected to delay the diffusion of *ibuprofen* into liquids and reduce the initial burst release. These scaffolds displayed meaningfully a reduced initial burst of *ibuprofen* releasing in the first hour (44).

Hyaluronic acid/ibuprofen nanofibers were fabricated with electrospinning method. Sustained release of drug molecules from all nanofibers was detected throughout the initial day by 40–60% of ibuprofen molecule releasing after first day (45). Gliadin/ibuprofen nanofibers were produced. In vitro experiments confirmed that the gliadin nanofibers with heterogeneous drug dispersal had less preliminary burst ibuprofen release and an extended time period releasing of 16 hours, signifying an improved sustained drug release profile than those nanofibers having a homogeneous drug dispersal that had plain initial burst release and a shorter release time period of 8 hour. The various ibuprofen dispersals have operated the different release performances of the loaded ibuprofen molecules, and therefore caused the dissimilar drug sustained release profiles (46).

PLA/ibuprofen nanofibers holding 10, 20, or 30 wt % drug were made. Two styles were seen while studying the release profiles. First, an increased temperature (37˚C) produced a superior release of ibuprofen from the nanofibers as compared to room temperature. Second, the 30 wt % ibuprofen overloaded nanofibers at 37˚C manufactured the highest ibuprofen release (~0.25 mg at 336 hours). At both room temperature and 37˚C, the results showed that a direct correlation occurred between ibuprofen concentration in the nanofibers and the quantity of ibuprofen released. PLA/ibuprofen nanofibrous were designed. The ibuprofen releasing mechanism is combined of degradation and diffusion. Practically 30% of loaded ibuprofen released in around 8 hours without any initial burst release and then 50% of entire ibuprofen has been released throughout only 4 hours (47).

Polyvinylpyrrolidone/ibuprofen nanofibrous mats were constructed by means of an electrospinning method. The results specified that the ibuprofen molecules had respectable compatibility with the polymer and that ibuprofen was well dispersed in the nanofibers as an amorphous physical form (48). Cellulose acetate/poly(vinyl pyrrolidone)/ibuprofen nanofibers were produced. These nanofibers showed a 3 phase releasing profile, an initial burst release, a succulents decelerating release and a constant release. Throughout the burst release phase, over 28 wt% of ibuprofen molecules were diffused from nanofibers that were owing to the distribution of ibuprofen molecules on the great surface of the nanofibers. At the succedent decelerating release phase, ibuprofen molecules in the internal of nanofibers diffused onto nanofibers surfaces. Through this procedure, ibuprofen molecules needed to overcome the Van der Waals’ force (or dispersion forces) produced between ibuprofen molecules and polymer matrix that reduced ibuprofen diffuse rate. In the latest release phase, the small concentration difference of ibuprofen between receptor solution and nanofibers made the releasing of ibuprofen became more problematic (49).

PLLA/ibuprofen nanofibers which have small amount of Ag nanoparticles were fabricated. The *in vitro* drug releasing analysis indicated a sustained release of Ag ions and *ibuprofen* molecules from the nanofibers. Throughout the first 2 days, burst releasing of *ibuprofen* from the nanofibers was 49.5%, followed by a sustained releasing in the following 10 days. Briefly, *ibuprofen* releasing performance depends chiefly on polymer matrix degradation, drug diffusion and Ag releasing (50).

In another work, the Poly(N-isopropylacrylamide)/Poly(ε-caprolactone)/ibuprofen nanofibers were constructed with Tran et al. These nanofibers confirmed a variable and controlled releasing at both room and higher temperature. The rate at 22˚C is 75% faster compared to that at 34˚C. The results showed that 1 μmol of ibuprofen was rapidly released from these nanofibers in the first hour at 22˚C, and then the rest drug was released at a considerable slower rate, 0.05 μmol hr⁻¹. Completely, 24% ibuprofen was released in four hours. In compare, ibuprofen was released at a more manageable style while the temperature was improved to 34˚C. The average release rate was ~0.2 μmol hr⁻¹ and ~0.4 μmol ibuprofen was released in the first one hour. Only 17% ibuprofen was released in 4 hours. This occurrence can be described with the great water solubility of Poly(N-isopropylacrylamide) when the temperature was below its LCST (32˚C), leading to the rapid ibuprofen releasing from the polymeric matrix. Though, Poly(N-isopropylacrylamide) converts greatly hydrophobic after temperature was above its LCST. Therefore Poly(N-isopropylacrylamide) functions similar a drug depot to forbid the rapid release of hydrophobic ibuprofen molecules, resulting in the comparatively more manageable release style (51).

In a different investigation, the PLLA/PLGA/ibuprofen nanofibers were prepared. The outcomes of an *in vitro* ibuprofen releasing displayed a burst release throughout the first 2 days with high initial ibuprofen amount. This initial phase was followed by a sustained release stage from nanfibres during the subsequent 10 days (52).

PLA/ibuprofen nanofibers were created. Two tendencies were detected while examining the ibuprofen release profiles. In the first stage, an increased temperature (37˚C) produced a superior releasing of drug from the nanofibers as compared to room temperature. In the second stage, PLA/ibuprofen(30%) nanofibers at 37˚C produced the maximum drug releasing. In both room temperature and 37˚C, the statistics recommended that a direct association be presented between ibuprofen amount in the nanofibers and the quantity of drug molecules released (53).

Cellulose acetate/Poly(vinyl pyrrolidone)/ibuprofen nanofibers were manufactured. These structures samples showed continued and steadily increasing release profiles (54). Polycaprolactone/ibuprofen nanofibers were prepared with Potrcˇ et al (55).

The releasing of *ibuprofen* from the PCL nanofibers was fast, reaching about 96% of the overall *ibuprofen* release in the first 4 hours from the nanofibers. The drug release rates from the PCL nanofibers loaded with various quantities of *ibuprofen* were not meaningfully different, representing that the changes in the nanofiber diameters and the surface morphology did not affect the release of the *ibuprofen* (55). A drug release test *in vitro* showed that the release rate of ibuprofen and ketoprofen was slow in PCL nanofibers loaded with drug–layered double hydroxide nanoparticles. After 5 days, only 44–48% of ibuprofen was released, whereas the release of ketoprofen was 20–25%. All nanofibers could release the drug after 5 days (56).

Release behavior of profens from nanofibrous drug delivery systems will be described in Table 2.
Table 2: Drug release behaviors of profens from nanofibrous mats.

| Material                          | Content load | Method     | In vitro study | Reference |
|-----------------------------------|--------------|------------|----------------|-----------|
|                                   |              |            | Ibuprofen release |            |
|                                   |              |            | Burst release   | Sustained |            |
|                                   |              |            | (in 2.5 hours)  | release   |            |
|                                   |              |            | (in 100%)      | (in 25   |            |
|                                   |              |            |                 | hours)    |            |
| Cellulose acetate solved in acetone/DMAC | Naproxen 9.39% | Mixing | 40% | 100%   | (57) |
| Polyvinylpyrrolidone solved in ethanol | ketoprofen | Mixing | 100% | ---     | (58) |
| Poly(vinyl alcohol) solved in deionized water | ketoprofen | Mixing | 58.43% (in 2 hours) | 83.82% (in 14 days) | (59) |
| Polyethylene oxide solved in methanol and water vapor; Silk and collagen solved in methanol and water vapor. with silk and collagen containing | Polyethylene oxide containing Flurbiprofen and coaxial process + + | Evaporation Flurbiprofen (in 1 day) | 33.1 µg/cm² | 72.2 µg/cm² | (60) |
| Poly(N-vinyl caprolactam) solved in distilled water and ethanol | Ketoprofen 10% | Mixing | 84% (in 4 minutes) | 98% | (61) |
| Poly(vinyl pyrrolidone) solved in EtOH and DMF; Poly(lactic-co-glycolic acid) solved in dichloromethane and DMF containing | Poly (lactic-co-glycolic acid) as sheath with Poly(vinyl pyrrolidone) containing | Mixing and coaxial process | 70% (in 24 hours) | 85% | (62) |
| Ketoprofen | Mixing | 50% (in 24 hours) | 73% | (in 4 days) in pH~2 | pH~2 |
| Material Description                                                                 | Drug      | Method                        | % Appearance | Time          | Ref. |
|-------------------------------------------------------------------------------------|-----------|-------------------------------|--------------|---------------|------|
| Chitosan and polyaniline solved in acetic acid                                      | Ketoprofen| Mixing and sequential process | 32%          | 1 hour        | (64) |
| Poly(vinylpyrrolidone) and zein solved in ethanol and water                         | Ketoprofen|                               | 72%          | 24 hours      | (63) |
| Chitosan solved in acetic acid and water;                                           | Naproxen 5%| Mixing                        | 25%          | 5 minutes     | (65) |
| Polyacrylic acid solved in sodium chloride and β-cyclodextrin;                      | Naproxen 5%|                               | 50%          | 2 minutes     | (65) |
| Poly(caprolactone) solved in acetic acid and formic acid                             | Naproxen 5%|                               | 25%          | 5 minutes     | (65) |
| Poly(vinyl alcohol) solved in water and phosphoric acid;                             | Naproxen 10%|                             | 40%          | 2 minutes     | (65) |
| Poly(lactic-co-glycolic acid) solved in N,N-dimethylformamide and tetrahydrofuran | Ibuprofen 5%| Mixing                       | 23%          | 5 days        | (66) |
| Polyvinylpyrrolidone and ethyl cellulose solved in ethanol                           | Naproxen 20%| Mixing                      | 30%          | 12 hours      | (67) |
| Pulp cellulose added to melted [BMIM]Cl                                              | Ibuprofen 2%| Mixing and dry–wet process | 48%          | 50 minutes    | (68) |
|                                                                                 | Ibuprofen 3%|                               | 48%          | (irrespective of its content) | (68) |
|                                                                                 | Ibuprofen 25%| Sol–gel                       | 68%          | 10 minutes    | (69) |
| Process Description                                                                 | Ibuprofen Concentration | Method          | Percentage 1   | Percentage 2   |
|----------------------------------------------------------------------------------|-------------------------|-----------------|----------------|----------------|
| Aluminum oxide added to distilled water and 2-butanol                             | 50%                     |                 | 73% (in 10 min) | 80% (in 7 h)   |
| Poly(vinylpyrrolidone) solved in ethanol                                          | 10%                     | Pressurized Gyr | 68% (in 10 min) | 100% (70 h)    |
| Gelatin solved in acetic acid                                                    | 33.2%                   |                 | 30% (in 3 d)    | 77±3.4 (3 d)    |
| +                                                                                |                         |                 |                |                |
| Poly(lactic acid) solved in chloroform                                             | 41.2%                   | Mixing          | 35% (in 3 d)    | 81.3±4.6% (3 d) |
| +                                                                                |                         |                 |                |                |
| Hydroxyapatite solved in water                                                    | 45.3%                   |                 | 40% (in 3 d)    | 92.1±2.8% (3 d) |
| +                                                                                |                         |                 |                |                |
| Ibuprofen 58.2%                                                                  |                         |                 | 50% (in 3 d)    | 95.8±2.1% (3 d) |
| Poly(vinyl alcohol), Chitosan, β-cyclodextrins                                    |                         |                 |                |                |
| Supercritical carbon dioxide assisted phase inversion                             |                         |                 | 60% (in 3 h)    | 90% (24 h)      |
| Zein solved in methanoic acid                                                     |                         |                 | 0.05 mg/mL⁻¹    |                |
| Poly(lactic acid) solved in dimethylformamide and chloroform                     | 10%                     | Mixing          | 0.05 mg (in 1 d)| 0.07 mg        |
| +                                                                                |                         |                 | (in 12 d)       |                |
| Ibuprofen 20%                                                                    |                         |                 | 0.11 mg (in 1 d)| 0.13 mg        |
| +                                                                                |                         |                 | (in 12 d)       |                |
| Ibuprofen 30%                                                                    |                         |                 | 0.21 mg (in 1 d)| 0.25 mg        |
| Cellulose Acetate solved in N,N-dimethylacetamide and acetone                     |                         |                 | 7.7% (in 4 h)   |                |
| Poly(caprolactone) solved in dichloromethyl and dimethyl formamide                | 10%                     | Mixing          | 98% (in 2 h)    |                |

J. Adv. Biomed. & Pharm. Sci.
| Material                                      | Ibuprofen | Deposition on | Concentration | Time (days) | Ref. |
|----------------------------------------------|-----------|---------------|---------------|-------------|------|
| Poly(L-lactide) solved in dichloromethane and N,N-dimethylformamide | 3.91±0.22% | 10% (6 hours)  | 20% in pH~7.4 | 40% in 6 days | (78) |
| Silk suture immersed in normal saline        |           | Mixing        | 0.75/µg cm⁻¹  | 40% in 6 days | (77) |
| Poly(lactic acid) solved in dichloromethane and N,N-dimethylformamide | 3.91±0.22% | 10% (6 days)  | 1.40/µg cm⁻¹  | 80% (35 days) | (78) |
| Poly(lactide-co-glycolide) solved in dichloromethane |           | Mixing        | 1.6 µ moles | 80% (35 days) | (79) |
| Cellulose Acetate solved in acetone/DMAc     | 7.1%      | Mixing        | 20% (1 hour) | 80% (1 day)  | (80) |
| Poly(lactide-co-glycolide) and poly(ethylene glycol)-g-chitosan solved in N,N-dimethylformamide | 5%        | Mixing        | 22% (1 day)  | 70% (16 days) | (81) |
| Poly(lactide-co-glycolide) solved in N,N-dimethylformamide | 5%        | Mixing        | 45% (1 day)  | 100% (12 days) | (80) |
| Poly(lactic-co-glycolic acid) solved in N,N-dimethylformamide and tetrahydrofuran | 5%        | Mixing        | 25% (3 days) | 80% (45 days) | (66) |
|                                             |           |               | 30% (1 day)  | 45.09       | (4.02%)
|                                             |           |               |               |              |      |
| Material Description | Ibuprofen Concentration | Method | Percentage | Time | Reference |
|----------------------|-------------------------|--------|------------|------|-----------|
| Poly(vinyl pyrrolidone) and Lysine solved in milli-Q water | Ibuprofen 5% | Mixing | 27.5% (in 1 day) | pH~5 | 29.17 | ±4.29% (in 1 day) | pH~8 | (82) |
| Polyvinylpyrrolidone solved in ethanol | No load | Ibuprofen 7.5% | Mixing | --- | --- | (48) |
| | | Ibuprofen 15% | --- | --- | --- | | | |
| Cellulose acetate and poly(vinyl pyrrolidone) solved in acetone and DMAc | Ibuprofen 20% | Mixing | 30% (in 1 hour) | 95% (in 1 day) | (49) |
| Gliadin solved in 1,1,1,3,3,3-hexafluoro-2-propanol and trifluoroacetic acid | Cellulose acetate 0% | Mixing and triaxial process | 34.2±4.5% (in 1 hour) | 100% | (83) |
| | Cellulose acetate 1% | --- | 8.3±4.6% | (in 2 days) | |
| | Cellulose acetate 3% | Mixing and coaxial process | 5.4±4.1 (in 1 hour) | (irrespective of its content) | |
| | Cellulose acetate 5% | --- | 2.7 ± 3.1% | (in 1 hour) | |
| | as sheath containing Ibuprofen as core | --- | --- | --- | | |
| Polyvinylpyrrolidone solved in distilled water | Ibuprofen 431.7 ± 39.7 µg/mL + 145.5 | Mixing | --- | --- | (84) |
| | ± 5.6 µg/mL acetylsalicylic acid | --- | --- | --- | |
| | Ibuprofen 528.3 ± 24.7 µg/mL + 168.3 ± 7.3 µg/mL acetylsalicylic acid | --- | --- | --- | |
| Poly(caprolactone) solved in chloroform and acetone | Ibuprofen 9.1% | Mixing | 72% (in 1 hour) | 95% (in 1 hour) | 100% | (55) |
| | Ibuprofen 13% | --- | 87% (in 1 hour) | (in 5 days) | |
| | Ibuprofen 23.1% | --- | 80% (in 1 hour) | (irrespective of its content) | |
| | Ibuprofen 28.6% | --- | 83% (in 1 hour) | |
| | Ibuprofen 33.3% | --- | 68% (in 1 hour) | |
| | Ibuprofen 37.5% | --- | --- | --- | |
| Material Description | Ibuprofen (%) | Method | % Remaining | % Remaining |
|----------------------|---------------|--------|-------------|-------------|
| Poly(caprolactone) solved in dichloromethane and acetone | 2.29% | Mixing | 40% (in 1 hour) | 80% (in 1 day) |
| No load | | | 23.5% Ag (in 2 days) | 48% Ag (in 10 days) |
| Poly(I-lactic acid) solved in dichloromethane and N,N-dimethylformamide | Ag 4% + Ibuprofen 4% | Mixing | 32.7% Ag (in 2 days) | 72% Ag (in 10 days) |
| | | | 35.9% Ag (in 2 days) | 88% Ag (in 10 days) |
| Poly(lactic-co-glycolic acid) and Poly(caprolactone) solved in dichloromethane and N,N-Dimethylformamide as core | Ibuprofen 5% | Mixing | 85% (in 24 hours) | 96% (in 13 days) |
| Gliadin solved in 1,1,1,3,3,3-hexafluoro-2-propanol containing traditional co-axial process | Ibuprofen 6.25% | Mixing and | 30% (in 2 hours) | 95% (in 1 day) |
| | Ibuprofen 11.76% | | 35% (in 2 hours) | |
| Poly(caprolactone) solved in dichloromethane and acetone | Ibuprofen 2% | Mixing | 40% (in 1 hour) | 75% (in 1 day) |
| Poly(ethylene glycol) /Poly(caprolactone) containing Ag as sheath | | Mixing and | 50% Ibuprofen (in 8 hours) | Ibuprofen |
| Poly(ethylene glycol) and Poly(caprolactone) solved containing hyaluronic acid | | process + | 80% hyaluronic acid (in 4 days) | + |
| Poly(caprolactone) containing Ag as sheath | | | 50% Ibuprofen (in 8 hours) | Ibuprofen |
| Poly(ethylene glycol) containing Ag as sheath | | | 50% Ibuprofen (in 8 hours) | Ibuprofen |
| Poly(ethylene glycol) and Poly(caprolactone) solved containing hyaluronic acid | | process + | 80% hyaluronic acid (in 4 days) | + |
4. Physical aspects of profen loaded nanofibrous mats

Physical properties of profen loaded nanofibrous mats will be reported in Table 3.

| Table 3: Physical characteristics of profen loaded nanofibrous mats. |
|---------------------------------------------------------------|
| **Profen loaded nanofibrous mats** | **Ultimate stress (MPa)** | **Ultimate strain (%)** | **Young’s modulus (MPa)** | **Reference** |
|----------------------------------|--------------------------|------------------------|---------------------------|---------------|
| Poly(vinylpyrrolidone) + zein + ketoprofen | 12                       | 14                     | ---                       | (64)          |
| Poly(lactic-co-glycolic acid) + Ibuprofen | ---                      | 140                    | ---                       | (66)          |
| Zein + Ibuprofen                 | 0.6                      | 99.7                   | ---                       | (73)          |
| Cellulose Acetate + Ibuprofen    | ---                      | 34.36                  | ---                       | (74)          |
| Gelatin + Ibuprofen              | 0.8±0.1                  | ---                    | 1.5-2.0                   | (88)          |
5. Structural characteristics of profen loaded nanofibrous meshes

Structural properties of profen loaded nanofibrous mats will be reported in Table 4.

Table 4: Structural characteristics of profen loaded nanofibrous mats.

| Ibuprofen loaded nanomaterials | Sample thickness (μm) | Pore size (μm) | Weight (mg/cm²) | Porosity (%) | Water contact (°) | Density (g/cm³) | Degree of swelling | Reference |
|-------------------------------|-----------------------|----------------|-----------------|--------------|-------------------|----------------|-------------------|-----------|
| Cellulose Acetate + Naproxen  | 409.3 ± 152.5         | ---            | ---             | ---          | ---               | ---            | ---               | (57)      |
| Poly(ethylene glycol) + Silk + Collagen + Flurbiprofen + Vancomycin | 422 ± 74          | ---            | ---             | ---          | ---               | ---            | ---               | (60)      |
| Poly(lactic-co-glycolic acid) + Flurbiprofen | 942               | ---            | ---             | 113          | ---               | ---            | ---               | (62)      |
| Poly(vinyl pyrrolidone) + Flurbiprofen | 286               | ---            | ---             | 78           | ---               | ---            | ---               |           |
|                | Value       | Error     | Percentage | Mass    |
|----------------|-------------|-----------|------------|---------|
| Polyvinylpyrrolidone + Ethyl cellulose + 20% Naproxen | 409±89      |           |            | (67)    |
| Poly(vinylpyrrolidone) + 10% Ibuprofen                | 1500        |           |            |         |
| Poly(vinyl alcohol) + Chitosan + β-cyclodextrins + Ibuprofen | 0.7±0.1     | 37±       |            | (72)    |
| Zein + Ibuprofen                                       | 605.6       |           |            | (73)    |
| Poly(lactic acid) + Ibuprofen 30%                      | 585.38±131  | 0.69      |            | (53)    |
| Poly(lactic acid) + Ibuprofen 20%                      | 478.31±167  | 0.67      | 87.9      |         |
| Poly(lactic acid) + Ibuprofen 10%                      | 329.11±249  | 0.428     |            |         |
| Cellulose Acetate + Ibuprofen                          | 533.5       |           |            | (74)    |
| Poly(caprolactone) + Ibuprofen 10%                     | 374±89      |           |            | (75)    |
| Silk + Ibuprofen                                        | 290±27      |           |            | (77)    |
| Poly(L-lactide) + Ibuprofen 3.87±0.31%                 | 1420±95     |           |            | (76)    |
| Poly(I-lactic acid) + Ibuprofen 3.91±0.22%             | 1350±280    |           |            | (78)    |
| Hydroxypropyl-β-cyclodextrin + Ibuprofen               | 180±95      |           |            | (89)    |
| Cellulose Acetate + Ibuprofen 7.1%                     | 297±14      |           |            | (80)    |
| Hydroxyapatite + Ibuprofen                             | 85±         | 1.40      |            | (88)    |
| Poly(caprolactone) + Ibuprofen 9.1%                    | 465±88      |           |            | (55)    |
| Poly(caprolactone) + Ibuprofen 13%                     | 454±83      |           |            |         |
| Poly(caprolactone) + Ibuprofen 23.1%                   | 593±105     |           |            |         |
| Poly(caprolactone) + Ibuprofen 28.6%                   | 568±97      |           |            |         |
| Poly(caprolactone) + Ibuprofen 33.3%                   | 582±109     |           |            |         |
| Poly(caprolactone) + Ibuprofen 37.5%                   | 686±196     |           |            |         |
| Hyaluronic Acid + 20% Ibuprofen                        | 520±16      |           |            | (45)    |
| Hyaluronic Acid + 30% Ibuprofen                        | 580±17      |           |            |         |
| Hyaluronic Acid + 40% Ibuprofen                        | 630±21      |           |            |         |
| Poly(I-lactic acid)                                    | 1020±26     | 131.3     |            | (50)    |

° ± 3.1°
|                         | Value 1 ± Error 1 | Value 2 ± Error 2 | Value 3 ± Error 3 | Value 4 ± Error 4 |
|-------------------------|-------------------|-------------------|-------------------|-------------------|
| Poly(I-lactic acid) + Ag 4% | 1140 ± 24         | ---               | 125.1             | ---               |
|                         | ±                 |                   | 4.1°              |                   |
| Poly(I-lactic acid) + Ag 4%+ Ibuprofen 4% | 1210 ± 37         | ---               | 126.8             | ---               |
|                         | ±                 |                   | 3.9°              |                   |
| Poly(I-lactic acid) + Ag 8% | 1180 ± 42         | ---               | 118.4             | ---               |
|                         | ±                 |                   | 2.7°              |                   |
| Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 5% Ibuprofen | 910±61            | ---               | 133.5             | ---               |
| Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 10% Ibuprofen | 1150±59           | ---               | 134.2             | ---               |
| Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 15% Ibuprofen | 1150±59           | ---               | 134.2             | ---               |
| Cellulose acetate/Poly(vinylpyrrolidone)+Ibuprofen | 385 ± 58          | ---               | ---               | ---               |
| Poly (lactic acid) + 10% Ibuprofen | 329.116 ±         | ---               | ---               | ---               |
|                         | 249.62            |                   |                   |                   |
| Poly (lactic acid) + 20% Ibuprofen | 478.316 ±         | ---               | 116.3             | ---               |
|                         | 167.61            |                   |                   |                   |
| Poly (lactic acid) + 30% Ibuprofen | 585.386 ±         | ---               | ---               | ---               |
|                         | 131.51            |                   |                   |                   |
| Poly (ε-caprolactone)+ 10% Ibuprofen | 1733              | ---               | ---               | ---               |
| Poly (ε-caprolactone)+Poly(N-isopropylacrylamide)+Ibuprofen | 551               | ---               | ---               | ---               |
| Poly(N-isopropylacrylamide) | 470               | ---               | ---               | ---               |
| Poly(lactic acid)+Polyethylene glycol+ 2% Ibuprofen | 1.40 ± 0.52       | ---               | 67.5              | 119.5             |
|                         | ±                 |                   | ± 3.1             |                   |
|                         | 5.8               |                   |                   |                   |
| Poly(lactic acid)+Polyethylene glycol+ 6% Ibuprofen | 1.32 ± 0.67       | ---               | 64.6              | 121.9             |
|                         | ±                 |                   | ± 3.2             |                   |
|                         | 8.1               |                   |                   |                   |
6. Kinetics of profen releasing from the nanofibrous webs

Table 5 represented the regression coefficients of mathematical models fitted to the releasing of profens from the nanofibrous mats.

Table 5: Suitable mathematical models fitted to the releasing of profen drugs from the nanofibrous webs.

| Nanofibrous web | Mathematical model | Suitable equation | Closeness of fit (R²) | Reference |
|-----------------|--------------------|-------------------|-----------------------|-----------|
| Poly(ethylene glycol) + Silk + Collagen + Flurbiprofen + Vancomycin | Wei-bull | \( C(t) = C_0 \left[ 1 - \exp \left( -\frac{(t - t_{lag})^3}{\tau} \right) \right] \) | 0.99 | (60) |
| Poly(N-vinylcaprolactam) + Ketoprofen | Korshmeier-Peppas | \( M_t = 72.4415 \times t^{0.0760} \times 10^{0.9695} \) | 0.9695 | (61) |
| Poly(lactic-co-glycolic acid) + Poly(vinyl pyrrolidone) + Flurbiprofen | First order | \( W = 52.50 \times e^{0.741t} + 68.13 \) | 0.9820 | (62) |
| | Zero order | \( W = 1.45t \) (in pH=2) | 0.606 | |
| | | \( W = 2.27t \) (in pH=6.7) | 0.550 | |
| | | \( W = 2.3t \) (in pH=7.4) | 0.502 | |
| | First order | \( \log (100-W) = \log 100 - 0.044t \) (in pH=6.7) | 0.954 | |
| | | \( \log (100-W) = \log 100 - 0.050t \) (in pH=7.4) | 0.971 | |
| Drug Combination                          | Model          | Equation                                                                 | Parameter \(K\) |
|-------------------------------------------|----------------|--------------------------------------------------------------------------|-----------------|
| Chitosan + Polyaniline + Ketoprofen       | Higuchi        | \[ W = 14.17t^{2/3} \text{ (in pH} - 2) \]                              | 0.967           |
|                                           |                | \[ W = 13.18t^{2/3} \text{ (in pH} - 6.7) \]                           | 0.993           |
|                                           |                | \[ W = 8.984t^{1/2} \text{ (in pH} - 7.4) \]                           | 0.989           |
|                                           | Hixson-Crowell | \[ (100 - W)^{1/3} = 100^{1/3} \text{ (in pH} - 2) \]                  | 0.708           |
|                                           |                | \[ -0.0245t \text{ (in pH} - 2) \]                                     |                 |
|                                           | Korsmeyer-Peppas | \[ (100 - W)^{1/3} = 100^{1/3} \text{ (in pH} - 6.7) \]              | 0.834           |
|                                           |                | \[ -0.0433t \text{ (in pH} - 6.7) \]                                   |                 |
|                                           |                | \[ (100 - W)^{1/3} = 100^{1/3} \text{ (in pH} - 7.4) \]              | 0.856           |
|                                           |                | \[ -0.0496t \text{ (in pH} - 7.4) \]                                   |                 |
|                                           |                | \[ M_t/M_{\infty} = 0.109t^{0.567} \text{ (in pH} - 2) \]            | 0.982           |
| Polyvinylpyrrolidone + Ethyl cellulose + 20% Naproxen | Korsmeyer-Peppas | \[ M_t/M_{\infty} = 0.118t^{0.579} \text{ (in pH} - 6.7) \] | 0.992 |
|                                           |                | \[ M_t/M_{\infty} = 0.107t^{0.675} \text{ (in pH} - 7.4) \]         | 0.980           |
| Cellulose + 3% Ibuprofen                  | Qt = \(Qt_0 + 1.03t\) |                                                                 | 0.9935          |
| Cellulose + 2% Ibuprofen                  | Qt = \(8.3544t^{0.4231}\) |                                                                 | 0.9388          |
| Poly (lactic acid) + 15 mg Ibuprofen      | Korsmeyer-Peppas | \[ M_t/Q_{\infty} = Kt^{0.40} \]                                   |                 |
| Poly (lactic acid) + 10 mg Ibuprofen      | Korsmeyer-Peppas | \[ M_t/M_{\infty} = Kt^{0.30} \]                                   | --              |
| Poly (lactic acid) + 5 mg Ibuprofen       | Korsmeyer-Peppas | \[ M_t/M_{\infty} = Kt^{0.18} \]                                   |                 |
| Poly(vinyl alcohol)+Chitosan+Ibuprofen    | Korsmeyer-Peppas | \[ M_t/M_{\infty} = Kt^n \]                                         | 0.96824         |
Conflict of interest

The authors declare that there is no conflict of interest regarding this review.

References:

[1] Doostmohammadi M, Forootanfar H, Ramakrishna S. Regenerative medicine and drug delivery: Progress via electrospun biomaterials. Materials Science and Engineering: C. 2020;109:110521.

[2] Bardović L, Kotizová A, Sievänen J, Grovová K, Židek O, Bárta T, Khulánek J, et al. Antimicrobial nanofibrous mats with controllable drug release produced from hydrophobized hyaluronic. Carbohydrate Polymers. 2021;267:118225.

[3] Bai Y, Wang D, Zhang Z, Pan J, Cui Z, Yu D-D, et al. Testing of fast dissolution of ibuprofen from its electrospun hydrophilic polymer nanocomposites. Polymer Testing. 2021;93:106872.

[4] Xing G, Shao L, Du Y, Tao H, Qi C. Citric acid crosslinked chitosan/polyethylene oxide) composite nanofibers fabricated by electrospinning and thermal treatment for controlled drug release. Cellulose. 2021;28(2):961-71.

[5] Gutscheidt M, Haza R, Zhou X, Xu X, Szabi M, Jiang L. Electrospun, sepilote-loaded polyvinyl alcohol/sol protein isolate nanofibers: Preparation, characterization, and their drug release behavior. International Journal of Pharmaceutics. 2021;594:120172.

[6] Contreras-Cáceres R, Cabeza L, Perazzoli G, Díaz A, López-Romero JM, Melguizo C, et al. Electrospun Nanofibers: Recent Applications in Drug Delivery and Cancer Therapy. Nanomaterials. 2019;9(4).

[7] Kajdiš S, Zupancič Š, Rolkar R, Kobeck P. The potential of nanofibers to increase solubility and dissolution rate of the poorly soluble and chemically unstable drug lovastatin. International Journal of Pharmaceutics. 2020;573:118809.

[8] Gupta P, Purwar R. Electrospun pH responsive poly (acrylic acid-co-acrylamide) hydrogel nanofibrous mats for drug delivery. Journal of Polymer Research. 2020;27(10):296.

[9] Yang J, Wang K, Yu D-G, Yang Y, Bligh SWA, Williams GR. Electrospun Janus nanofibers loaded with a drug and inorganic nanoparticles as an effective antibacterial wound dressing. Materials Science and Engineering: C. 2020;111:110805.

[10] Jain R, Shetty S, Yadav KS. Unfolding the electrospinning potential of biopolymers for preparation of nanofibers. Journal of Drug Delivery Science and Technology. 2020;57:101604.

[11] Sun Y, Cheng S, Lu W, Wang Y, Zhang P, Yao Q. Electrospun fibers and their application in drug controlled release, biological dressings, tissue repair, and enzyme immobilization. RSC Advances. 2019;9(44):25712-29.

[12] Ismail HM, Ali-Adli S, Younes HM. Reactive and functionalized electrospun polymeric nanofibers for drug delivery and tissue engineering applications. Therapeutic Delivery. 2019;10(7):397-9.

[13] Moydeen AM, Ali Padusha MS, Abolfetoh EF, Al-Deyab SS, El-Newehy MH. Fabrication of electrospun polyvinyl alcohol/dextran nanofibers via emulsion process as drug delivery system: Kinetics and in vitro release study. International Journal of Biological Macromolecules. 2018;116:1250-9.

[14] Unnithan AR, Sasikala ARK, Murugesan P, Gurusamy M, Wu D, Park CH, et al. Electrospun polyurethane-dextran nanofiber mats loaded with Estradiol for postmenopausal wound dressing. International Journal of Biological Macromolecules. 2015;77:1-8.

[15] Nouri A, Faraji Dizaji B, Kianinejad N, Jafari Rad A, Rahimi S, Irani M, et al. Simultaneous linear release of folic acid and doxorubicin from ethyl cellulose/chitosan/g-C3N4/Mo52 core-shell nanofibers and its anticancer properties. Journal of Biomedical Materials Research Part A. 2021;109(6):903-14.

[16] Faraji Dizaji B, Hasanizadeh Z, Sheibani N, Goleij P, Mirmajidi T, Chogan F, et al. Synthesis of PLGA/chitosan/zeolites and PLGA/chitosan/metal organic frameworks nanofibers for targeted delivery of Paclitaxel toward prostate cancer cells death. International Journal of Biological Macromolecules. 2020;164:1461-74.

[17] Cao C, Keirouz A, Chen X, Radaci N. Electrospun Nanofibers for Drug Delivery and Biosensing. ACS Biomaterials Science & Engineering. 2019;5(9):4183-205.

[18] Tort S, Han D, Stecki AJ. Self-inflating floating nanofiber membranes for controlled drug delivery. International Journal of Pharmaceutics. 2020;579:119164.

[19] Tuğçu-Demiröz F, Saar S, Tort S, Acarťürk F. Electrospun metronidazole-loaded nanofibers for vaginal drug delivery. Drug Development and Industrial Pharmacy. 2020;46(6):1015-25.

[20] Göttel B, de Souza e Silva JM, Santos de Oliveira C, Syrovatka F, Florentzis M, Viestenz A, et al. Electrospun nanofibers – A promising solid in-situ gelling alternative for ocular drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2020;146:125-32.

[21] Farokhi M, Mottaghibalab F, Reis RL, Ramakrishna S, Kundu SC. Functionalized silk fibroin nanofibers as drug carriers: Advantages and challenges. Journal of Controlled Release. 2020;321:324-47.

[22] Zandi N, Lotfi R, Tamjjid E, Shokrgozar MA, Simchi A. Core-sheath gelatin based electrospun nanofibers for dual delivery of biomolecules and therapeutics. Materials Science and Engineering: C. 2020;110:14342.

[23] Sa’don S, Abd Razak SI, Ismail AE, Fakhruddin K. Drug-Loaded Poly-Vinyl Alcohol Electrospun Nanofibers for Transdermal Drug Delivery: Review on Factors Affecting the Drug Release. Procedia Computer Science. 2019;158:436-42.

[24] Khodadadi M, Alijani S, Montazeri M, EsmaeiliZadeh N, Sadeghi-Soureh S, Pilehvar-Soltanahmadi Y. Recent advances in electrospun nanofiber-mediated drug delivery strategies for localized cancer chemotherapy. Journal of Biomedical Materials Research Part A. 2020;108(7):1444-58.

[25] Weso M, Razak SIA, Bohari SPM, Shahir S, Salihu R, Kadir MRA, et al. Vitamin D3-loaded electrospun cellulose acetate/polyacrylactone nanofibers: Characterization, in-vitro drug release and cytotoxicity studies. International Journal of Biological Macromolecules. 2021;181:82-98.

[26] Chen R, Lin L, Wang H, Zhai X, Liang Y, Zhao B, et al. Effects of Morphologies of Thermosensitive Electrospun Nanofibers on Controllable Drug Release. Tissue Engineering Part A. 2020;27(11-12):724-32.

[27] Meneguin AB, da Silva Barud H, Sábio RM, de Sousa PZ, Manieri KF, de Freitas LAP, et al. Spray-dried bacterial cellulose nanofibers: A new generation of pharmaceutical excipient intended for intestinal drug delivery. Carbohydrate Polymers. 2020;249:116838.

[28] Kharaghani D, Gitigard P, Ohtani H, Kim KO, Ullah S, Salito Y, et al. Design and characterization of dual drug delivery based on in-situ assembled PVA/PAN core-shell nanofibers for wound dressing application. Scientific Reports. 2019;9(1):12640.

[29] Huang C-K, Zhang K, Gong Q, Yu D-G, Wang J, Tan X, et al. Ethylcellulose-based drug nano depot fabricated using a modified triaxial electrospinning. International Journal of Biological Macromolecules. 2020;152:68-76.

[30] Khaliili Amand F, Esmeeali A. Investigating the properties of electrospun nanofibers made of hydroxy polymer containing anticoagulant drugs. Carbohydrate Polymers. 2020;228:115397.

[31] Jiang Y-N, Mo H-Y, Yu D-G. Electrospun drug-loaded core–sheath PVP/zein nanofibers for biphasic drug release. International Journal of Pharmaceutics. 2012;438(1):232-9.

[32] Zhang X, Chi C, Chen J, Zhang X, Gong M, Wang X, et al. Electrospun quadaxial nanofibers for controlled and sustained drug delivery. Materials & Design. 2021;206:109732.

[33] Tavanez MA. Drug Delivery of Nanofibers Based on Biodegradable Synthetic Polymeric Blends: A Review. Baspasrem. 2017;7(2):13-29.

[34] Yan E, Jiang J, Yang X, Fan L, Wang Y, An Q, et al. pH-sensitive core-shell electrospun nanofibers based on polyvinyl alcohol/polyacrylactone as a potential drug delivery device for the chemotherapy against cervical cancer. Journal of Drug Delivery Science and Technology. 2020;55:101455.

[35] Celebioglu A, Uyar T. Hydrocortisone/cyclodextrin complex electrospun nanofibers for a fast-dissolving oral drug delivery system. RSC Medicinal Chemistry. 2020;11(2):245-58.

[36] Sofi HS, Abdalhay A, Ivanovski S, Zhang YS, Sheikh FA. Electrospun nanofibers for the delivery of active drugs through nasal, oral and vaginal mucosa: Current status and future perspectives. Materials Science and Engineering: C. 2020;111:110756.
[37]Najiah N, Murdock CJ, Bhattacharjee M, Nair L, Laurencin CT. Development of Tripolymeric Triaxial Electrospun Fibrous Matrices for Dual Drug Delivery Applications. Scientific Reports. 2020;10(1):609.

[38]Fattahi F, Khoddami A, Avic O. Poly (Lactic Acid) Nanofibers as Drug Delivery Systems: Opportunities and Challenges. Nanomedicine Research Journal. 2019;4(3):130-40.

[39]Guo H, Tan S, Gao J, Wang L. Sequential release of drugs form a dual-delivery system based on pH-responsive nanofibrous mats towards wound care. Journal of Materials Chemistry B. 2020;8(8):1759-70.

[40]Xie M, Yang M, Sun X, Yang N, Deng T, Li Y, et al. WS2 nanosheets functionalized by biomimetic lipids with enhanced dispersibility for photothermal and chemo combination therapy. Journal of Materials Chemistry B. 2020;8(11):2341-52.

[41]Hou J, Yang J, Zheng X, Wang M, Liu Y, Yu D-G. A nanofiber-based drug delivery system for sustained release. International Journal of Pharmaceutics. 2020;583:113997.

[42]Day RO, Graham GG, Williams K. Propionic Acid Derivative Drugs (Profens). In: Parnham MJ, editor. Compendium of Inflammatory Diseases. Basel: Springer Basel; 2016. p. 1106-10.

[43]Duggan KC, Herrmann DJ, Musee J, Prusakiewicz JJ, Scheib JL, Carter BD, et al. (R)-Profens are substrate-selective inhibitors of endothoamil oxidase. Biochemistry. 2011;50(23):4076-82.

[44]Mao Y, Chen M, Guidoin R, Li Y, Wang F, Brochu G, et al. Potential of a facile sandwiched electrospun scaffold loaded with ibuprofen as an anti-adhesion barrier. Materials Science and Engineering: C. 2021;118:114151.

[45]Chen CT, Chen CH, Sheu C, Chen JP. Ibuprofen-Loaded Hyaluronic Acid Nanofibrous Membranes for Prevention of Postoperative Tendon Adhesion through Reduction of Inflammation. Int J Mol Sci. 2019;20(20).

[46]Xu X, Li J, Williams GR, Yang JH, Wang X. Influence of the drug in electrospun gelatin fibers on drug-release behavior. Eur J Pharm Sci. 2017;106:424-30.

[47]Jamshidi-Adegan F, Seyedyafar J, Gheibi N, Soleimani M, Samahani S. Prevention of adhesion barriers by ibuprofen-loaded PLGA nanofibers. Biotechnol Prog. 2016;32(4):990-7.

[48]Yu D-G, Zhang X-F, Shen X-X, Brandford-White C, Zhu L-M. Ultrasound-responsive ibuprofen-loaded polylactide-co-3-hydroxypropionic acid fiber mats by electrospinning. Polymer International. 2009;58(9):1010-3.

[49]Shi Y, Wei Z, Zhao H, Liu T, Dong A, Zhang J. Electrospinning of ibuprofen-loaded composite nanofibers for improving the performances of transmucosal patches. J Nanosci Nanotechnol. 2013;13(6):3855-63.

[50]Chen S, Wang G, Wu T, Zhao X, Liu S, Li G, et al. Silver nanoparticles/ibuprofen-loaded poly(l-lactide) fibre membrane: anti-infection and anti-adhesion effects. International journal of molecular sciences. 2014;15(8):14014-25.

[51]Tran T, Hernandez M, Patel D, Burns E, Peterman V, Wu J. Controllable and switchable drug delivery of ibuprofen from temperature responsive composite nanofibers. Nano Convergence. 2015;2(1):15.

[52]Liu S, Hu C, Li F, Li X, Cui W, Fan C. Prevention of peritendinous adhesions with electrospun ibuprofen-loaded poly(L-lactic acid)-polyethylene glycol fibrous membranes. Tissue Eng Part A. 2013;19(3-4):329-37.

[53]Marson J, Lai S, Scuderi M, Guo J, Szpunar M, Atala A, et al. Ibuprofen loaded PLA nanofibrous scaffolds increase proliferation of human skin cells in vitro and promote healing of full thickness incision wounds in vivo. J Biomed Mater Res B Appl Biomater. 2017;105(2):327-39.

[54]Shi Y, Xu S, Dong A, Zhang J. Design and in vitro evaluation of ibuprofen-loaded polyethylene glycol/zein electrospun scaffold for tissue regeneration. Biotechnology and Applied Biochemistry. 2014;63:39-47.

[55]Tan T, Wang H, Ponomarenko DA, Tungprapa S, Jangchud I, Supaphol P. Release characteristics of four ibuprofen loaded PVA/chitosan membranes: A high efficiency strategy towards an improved skin wound healing. Carbohydrate Polymers. 2017;159:136-45.

[56]Quri H, Xiang LQ. Synthesis of Electrospun Zein and Silk Fibroin/Zein Meshes with Ibuprofen for Drug Delivery to Chronic Wounds. Thesis. 2018.

[57]SATRIAWAN NE. Sintesis Dan Karakterisasi Nanofiber Selulosa Asetat Penambahan Ibuprofen Sebagai Model Sistem Penghantar Obat. Thesis, Universitas Airlangga. 2017.

[58]Batool F, Morand DN, Thomas L, Bugueno IM, Aragon J, Irusta S, et al. Synthesis of a Novel Electrospun Polycaprolactone Scaffold Functionalized with Ibuprofen for Periodontal Regeneration: An In Vivo and In Vivo Study. Materials. 2018;11(10):119.

[59]Quri H, Zhao J, Zhu W, Yang Z, Li B, Yang H, et al. Ibuprofen loaded electrically conducting poly(lactic-co-glycolic acid) core-shell composite nanofibers: A controlled release medicinal nanocarrier system for photothermal and chemo combination therapy. Journal of Materials Chemistry B. 2017;5:990-4.

[60]Shen Z, Zang J, Yang Z, Li B, Yang H, Cui W, et al. Synergistic Effect of Regeneration and Inflammation via Ibuprofen-Loaded Electrospun Fibrous Scaffolds for Repairing Skeletal Muscle. European Journal of Pharmacology. 2014;712(1-2):1-7.

[61]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.

[62]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.

[63]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.

[64]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.

[65]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.

[66]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.

[67]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.

[68]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.

[69]Bi D, Hua M, Sun X, Yang JH, Zheng X, Wang M, et al. Electrospun gelatin fibers for drug release delivery. Int J Pharm. 2012;430(1):82-9.
[83] Yang Y, Li W, Yu D-G, Wang G, Williams GR, Zhang Z. Tunable drug release from nanofibers coated with blank cellulose acetate layers fabricated using tri-axial electrospinning. Carbohydrate Polymers. 2019;203:228-37.
[84] Maslakci NN, Ulusoy S, Uygun E, Çevikbaş H, Oksuz I, Can HK, et al. Ibuprofen and acetylsalicylic acid loaded electrospun PVP-dextran nanofiber mats for biomedical applications. Polymer Bulletin. 2017;74(8):3283-99.
[85] Shalumon KT, Sheu C, Chen CH, Chen SH, Jose G, Kuo CY, et al. Multi-functional electrospun antibacterial core-shell nanofibrous membranes for prolonged prevention of post-surgical tendon adhesion and inflammation. Acta Biomater. 2018;72:121-36.
[86] Hu C, Liu S, Zhang Y, Li B, Yang H, Fan C, et al. Long-term drug release from electrospun fibers for in vivo inflammation prevention in the prevention of peritendinous adhesions. Acta Biomater. 2013;9(7):7381-8.
[87] Liu S, Hu C, Li F, Li X-J, Cui W, Fan C. Prevention of Peritendinous Adhesions with Electrospun Ibuprofen-Loaded Poly(l-Lactic Acid)-Polyethylene Glycol Fibrous Membranes. Tissue Engineering Part A. 2012;19(3-4):529-37.
[88] Sahmani S, Khandan A, Saber-Samandari S, Mohammadi Aghdam M. Effect of magnetite nanoparticles on the biological and mechanical properties of hydroxyapatite porous scaffolds coated with ibuprofen drug. Materials Science and Engineering: C. 2020;111:110835.
[89] Celebioglu A, Uyar T. Fast Dissolving Oral Drug Delivery System Based on Electrospun Nanofibrous Webs of Cyclodextrin/Ibuprofen Inclusion Complex Nanofibers. Molecular pharmaceutics. 2019;16(10):4387-98.
[90] Immich APS, Arias ML, Carreras N, Boemo RL, Tornero JA. Drug delivery systems using sandwich configurations of electrospun poly(lactic acid) nanofiber membranes and ibuprofen. Materials Science and Engineering: C. 2013;33(7):4002-8.
[91] Celik G, Oksuz AU. Controlled Release of Ibuprofen From Electrospun Biocompatible Nanofibers With In Situ QCM Measurements. Journal of Macromolecular Science, Part A. 2015;52(1):76-83.